124 results
Page 3 of 7
8-K
EX-99.1
24sn7i
4 Apr 23
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
6:05am
8-K
EX-10.1
d10b680badk8tl7k
4 Apr 23
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
6:05am
424B5
n01e56eqdunegdwciux
4 Apr 23
Prospectus supplement for primary offering
6:03am
8-K
EX-99.1
tofm15od 2mp
31 Mar 23
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
6:00am
8-K
EX-10.1
ewm3ahm
16 Dec 22
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
7:05am
8-K
EX-99.1
8hkf2d t392i6
16 Dec 22
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
7:05am
424B5
pfnt22uw6qmidqnbgo
16 Dec 22
Prospectus supplement for primary offering
7:00am
8-K
EX-99.1
kvcuo4u70rw7v0pjsz
5 Dec 22
Checkpoint Therapeutics Announces Reverse Stock Split
4:45pm
DEF 14C
ptj8p41cqkhg cg462
14 Nov 22
Information statement
5:00pm
8-K
EX-99.1
txneg9pa 6osncxcmpru
8 Nov 22
Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
5:43pm
PRE 14C
lz8qtbkgpyc12k9s5f4
4 Nov 22
Preliminary information
5:22pm
8-K
EX-99.1
nd6fjegght4 44s
12 Aug 22
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
8:15am
8-K
EX-99.1
9y1 fvylimw
16 Jun 22
Other Events
7:45am
8-K
EX-99.1
3hdepd 6es3
12 May 22
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
4:45pm